Curriculum Vitae

Hadley Spencer, FNP-C

Practice Address:

Oncology Specialists of Charlotte
2711 Randolph Road, Suite 400
Charlotte, NC 28207
hspencer@oncologycharlotte.com

Site Affiliations:

DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

2015	Master of Science Francis Marion University Florence, South Carolina Specialty: Family Nurse Practitioner
2011	Bachelor of Science in Nursing Clemson University Clemson, South Carolina

Professional Experience:

2016-Present	Family Nurse Practitioner Oncology Specialists of Charlotte
2015-2016	Family Nurse Practitioner Colonial Family Practice
2012-2016	Clinical Supervisor Urgent Care
2011-2015	Registered Nurse Colonial Family Practice

Certifications:

Present - 2020	AHA Advanced Cardiovascular Life Support
Present - 2020	AHA BLS

Professional Organizations:

Oncology Nursing Society
American Academy of Nurse Practitioners

Clinical Research:

Sub- Investigator – ARMO Biosciences Cypress 1: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression.

Sub- Investigator – Incyte: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy.

Sub- Investigator – Amgen: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN.

Sub- Investigator – Amgen: An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers.

Sub- Investigator –Boehringer Ingelheim Pharmaceuticals, Inc: XENERA™-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease.

Sub- Investigator – Regeneron: Cemiplimab Survivorship Epidemiology (CASE) Study

Sub- Investigator – Astrazeneca: An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment. 2019

Sub- Investigator – Incyte: Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). 2019

Sub- Investigator – Novocure: LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure

Sub- Investigator – SecuraBio Inc: A Disease Registry Encompassing the Care of Patients with Multiple Myeloma on Panobinostat (RECOMM)

Sub-Investigator – GSK: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer

Sub-Investigator – Incyte: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Sub-Investigator – Fibrogen: A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)

Sub-Investigator – BMS/Labcorp: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Sub-Investigator – Myovant: A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX®

Sub-Investigator – Regeneron: A Phase 1/2 Study Of Cemiplimab (Anti-PD-1 Antibody) In Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy In First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Sub-Investigator – UBC: Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.

Hadley Spencer, NP
Signature

12/8/22
Date